Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.
Dana BakdachReem ElajezAbdul Rahman BakdachAhmed AwaisuGennaro De PascaleAli Ait HssainPublished in: Journal of clinical medicine (2022)
Critically ill patients presenting with special circumstances might be at risk of altered NBLA pharmacokinetics, particularly in the settings of ARC and RRT. More robust, well-designed trials are still required to define effective dose regimens able to attain therapeutic PK/PD indices of NBLA when utilized in those special scenarios, and thus aid in improving the patients' outcomes.
Keyphrases
- extracorporeal membrane oxygenation
- end stage renal disease
- acute respiratory distress syndrome
- chronic kidney disease
- ejection fraction
- metabolic syndrome
- newly diagnosed
- type diabetes
- insulin resistance
- climate change
- gram negative
- peritoneal dialysis
- prognostic factors
- multidrug resistant
- weight loss
- respiratory failure
- patient reported outcomes
- skeletal muscle
- body mass index
- intensive care unit
- high fat diet induced
- glycemic control
- adipose tissue
- patient reported
- mechanical ventilation